Piramal Pharma — FDA GMP Inspection & Price Action

As on December 12, 2025,

was in focus after the US FDA general GMP inspection at its Lexington, Kentucky facility (Dec 3–10) resulted in a Form 483 with four observations that are classified as VAI (Voluntary Action Indicated). These relate to procedural enhancements and are not classified as Official Action Indicated, which is generally seen as less severe. On a month-to-date basis in Dec 2025, the stock has corrected ~6%, reflecting the broader negative trend. However, the last two trading sessions turned positive, suggesting short-term buying interest. In the near term, the market will likely weigh recent positive momentum against the prevailing downtrend, with participation, sectoral cues, and broader market breadth shaping price behavior. Investors often watch key levels and volume to gauge whether momentum sustains or whether the dominant trend reasserts itself. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. AI may have been used for grammatical and sentence-structure refinement. Please consult a SEBI-registered advisor before making any investment decisions.